Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA

P. J. de Vries, W. F. van der Meide, M. H. Godfried, H. D. F. H. Schallig, H. J. Dinant, W. R. Faber

Research output: Contribution to journalArticleAcademicpeer-review

20 Citations (Scopus)

Abstract

A male patient with psoriatic arthritis and visceral Leishmania infantum infection was treated with oral miltefosine 50 mg three times a day for 4 weeks at the Academic Medical Center, Amsterdam, The Netherlands. Miltefosine plasma concentrations were measured with liquid chromatography/mass spectrometry. The parasite load was followed by quantitative nucleic acid sequence-based amplification (QT-NASBA) assay in blood. Miltefosine elicited a prompt therapeutic effect. After an initial worsening of symptoms and an increase of QT-NASBA values during the first week, recovery was rapidly achieved. QT-NASBA values declined exponentially and were negative after 6 weeks. Miltefosine plasma concentrations continued to accumulate during the 4 weeks of treatment. The terminal elimination half-life was 14.8 days
Original languageEnglish
Pages (from-to)1183-1186
JournalTransactions of the Royal Society of Tropical Medicine and Hygiene
Volume100
Issue number12
DOIs
Publication statusPublished - 2006

Cite this